Stephan Reichl

Dr. Stephan Reichl

Institute of Pharmaceutical Technology and Biopharmaceutics, Technische Universität Braunschweig, 38106 Braunschweig, Germany
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAAnthony A. Attama
Anthony A. Attama
SRStephan Reichl
Stephan Reichl
CMChristel C. Müller-Goymann
Christel C. Müller-Goymann

1 May 2011 in Biomaterials
Verified
Journal Article
Closed access
SRStephan Reichl
Stephan Reichl
MBMaria Borrelli
Maria Borrelli
GGGerd Geerling
Gerd Geerling

1 February 2010 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
AWAnnette Wengst
Annette Wengst
SRStephan Reichl
Stephan Reichl

1 April 2004 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
SRStephan Reichl
Stephan Reichl
JBJ Bednarz
J Bednarz
CMC C Müller-Goymann
C C Müller-Goymann
Aims: For the study of transcorneal in vitro permeation of ophthalmic drugs, excised animal cornea or corneal epithelial cell culture are frequently used as a replacement for the human cornea. The main purposes of this study were to reconstruct a complete human organotypic cornea equivalent, consisting of all three different cell types (epithelial, stromal, and endothelial); to test the barrier function of this bio-engineered human cornea using three different model drugs (pilocarpine hydrochloride (PHCl), befunolol hydrochloride (BHCl), and hydrocortisone (HC)); and to determine its usefulness as an in vitro model for prediction of ocular drug absorption into the human eye. Methods: A multilayer tissue construct was created step by step in Transwell cell culture insert using SV-40 immortalised human endothelial and epithelial cells and native stromal cells (fibroblasts). Morphology was characterised by light microscopy using routine H&E staining. Scanning electron microscopy was used to evaluate ultrastructural features. Ocular permeation of drugs across the human cornea construct was tested using modified Franz cells and compared with data obtained from excised porcine cornea and previously described porcine cornea constructs. Results and conclusion: The cornea construct exhibited typical corneal structures such as a monolayer of hexagonally shaped endothelial cells and a multilayered epithelium consisting of seven to nine cell layers with flat superficial cells. The formation of microplicae and microvilli was also confirmed. The human cornea construct showed similar permeation behaviour for all substances compared with excised porcine cornea. However, permeability (permeation coefficients Kp) of the human cornea equivalent (PHCl 13.4•10−6 (SD 3.01•10−6); BHCl 9.88•10−6 (SD 1.79•10−6); HC 5.41•10−6 (SD 0.40•10−6) cm/s) was about 1.6–1.8 fold higher than excised porcine cornea. Compared with data from the porcine cornea construct the cultivated human equivalent showed a decreased permeability. The reconstructed human cornea could be appropriate to predict drug absorption into the human eye.

26 November 2018 in Metallomics
Verified
Journal Article
Open access
PDF file
CSClaudia Schmidt
Claudia Schmidt
LALucia Albrecht
Lucia Albrecht
SBShantheya Balasupramaniam
Shantheya Balasupramaniam
RMRainer Misgeld
Rainer Misgeld
BKBianka Karge
Bianka Karge
IOIngo Ott
Ingo Ott
Gold complexes with N-heterocyclic carbene (NHC) ligands have been attracting major attention in medicinal inorganic chemistry based on their favorable antiproliferative effects and the structural versatility of the coordinated NHC ligands. Here we present a novel complex of the type (NHC)2Au+, which represents a substantially improved and selective TrxR inhibitor compared to close structural analogues. The complex is highly stable in various solutions over 96 hours, however, comparative cellular uptake studies indicate metabolic transformations inside cells over time. A portfolio of other gold complexes (e.g. Auranofin) has been used as references in key biological assays, showing that the novel (NHC)2Au+ complex exhibits substantially lower protein binding in combination with a strongly enhanced cytotoxic activity.